While epidermal growth factor receptor (EGFR) fusions in non-small cell lung cancer (NSCLC) typically show sensitivity to tyrosine kinase inhibitors (TKIs), we identified an EGFR-SHC1 fusion subtype that exhibits intrinsic resistance to EGFR-TKI monotherapy through a dual activation mechanism in the preclinical and clinical setting. EGFR-SHC1 fusion protein comprises of N-terminal EGFR and C-terminal SHC1. We demonstrated that EGFR-SHC1 simultaneously activates the EGFR kinase domain (KD) and SRC-mediated phosphorylation of the SHC1 fusion partner, thereby driving ERK/AKT pathway activation and tumorigenesis independent of KD inhibition. Structural modeling coupled with domain-specific mutagenesis revealed that SHC1 phosphorylation establishes a kinase-independent bypass mechanism. Notably, dual-targeted inhibition using afatinib (EGFR-TKI) in combination with dasatinib (SRC-TKI) induced marked tumor regression in a TKI-refractory NSCLC patient with EGFR-SHC1. This study illustrates a cooperative oncogenesis between kinase and scaffold protein in fusions, providing a clinically actionable strategy for overcoming TKI resistance in patients with these oncogenic fusions.
Supplementary Table S2 shows that individual clinicopathologic data have been reported in NSCLC patients with EGFR-fusions that were treated with EGFR-TKIs.
Supplementary Figure S1 shows the identification and validation of the EGFR-SHC1 fusion in NSCLC patients, including RT-PCR and Sanger sequencing confirmation, as well as the oncogenic potential of EGFR-SHC1 demonstrated through immunoblotting, flow cytometry, soft agar colony formation, and IL-3-independent proliferation assays in transfected Ba/F3 and NIH3T3 cells. It also presents structural modeling of EGFR-SHC1 binding to three EGFR-TKIs and the corresponding binding energy calculations.
Supplementary Figure S3 shows that both the N-terminal EGFR kinase domain and the C-terminal SHC1 phosphorylation sites contribute to the oncogenic properties of EGFR-SHC1, including analyses of SHC1 phosphorylation in response to EGF stimulation, TKI sensitivity in Ba/F3 cells, and functional assessments via soft agar colony formation and IL-3-independent proliferation assays using various EGFR-SHC1 mutants. It also includes immunoblotting validation of protein expression and downstream signaling in cells expressing EGFR-RAD51 and EGFR-SHC1 variants.
Supplementary Figure S2 shows that inactivation of the N-terminal EGFR kinase domain only partially abrogates the tumorigenicity of EGFR-SHC1, as demonstrated by soft agar colony formation assays. It also presents dose-response curves comparing the sensitivity of EGFR-RAD51 and EGFR-SHC1 to three EGFR-TKIs, along with immunoblotting analyses of downstream signaling inhibition following TKI treatment.